Project Grant R01HL173056
Award Date
6/1/25
Completion Date
3/31/29
Dollars Obligated
$770K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $758,862 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Yale University. This grant supports the development of a multimodality imaging approach to guide the percutaneous, transthoracic, epicardial delivery of therapeutic hydrogels to the myocardial infarction (MI) region in a porcine model. The research aims to evaluate the early mechanical and molecular mechanisms underlying the therapeutic...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This $580,863 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), supports research to develop improved cardiac regenerative therapies using engineered human cardiac organoids. The key products and services being delivered include: Optimizing the electrical properties and surface roughness of silicon nanowires incorporated into the cardiac organoids to enhance their interaction with human pluripotent stem...
This $496,367 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel approaches for in situ cardiac reprogramming. The key objectives are to: Investigate the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing if knockdown of individual repressors can recapitulate the effects of combined knockdown. Determine if targeting the repressor complex...
This $560,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support preclinical testing of a novel "triple gene therapy" approach to treat ischemic heart failure. The grantee, Baylor College of Medicine, will evaluate the optimal dosage and therapeutic window for a combination gene therapy involving induction of cardiomyocyte proliferation, direct cardiac reprogramming, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $259,464 to The Leland Stanford Junior University to study the effects of combining mitochondria-based therapies with existing heart failure treatments. The key objectives are to determine the protective mechanisms of mitochondria-rich extracellular vesicles (M-EVs) when used in conjunction with guideline-directed medical therapy (GDMT)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research under the Cardiovascular Diseases Research program (CFDA 93.837). The $117,804 award to The Leland Stanford Junior University (Stanford University) aims to investigate the role of macrophages and T-cell recruitment in immune checkpoint inhibitor-induced myocarditis, a life-threatening side effect of cancer immunotherapies. Specifically,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,408,580 to evaluate the AMPK-BACH1-NRF2 signaling pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM)-associated heart failure. The primary awardee, The Leland Stanford Junior University, will conduct this research using human induced pluripotent stem cell cardiomyocytes and a mouse model of DCM. The...
This federal Project Grant award, totaling $385,381.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The objective is to develop and evaluate injectable, dynamic silk-based hydrogels containing fetal cardiac extracellular matrix (CECM) to promote mechanical stabilization and favorable remodeling of the infarcted ventricular wall following myocardial infarction. The research will assess the impact of...